Secarna’s next-gen oligos

Why Secarna is developing antisense oligonucleotides for immuno-oncology

Secarna Pharmaceuticals GmbH’s antisense oligonucleotides for immuno-oncology could have better tissue penetration than small molecules and antibodies against the same targets.

The company was established in 2015 by the founders and investors who launched antisense company Sterna Biologicals GmbH & Co., which is focused on developing inflammatory lung and skin diseases. Sterna’s lead program, SB010, is in Phase II

Read the full 596 word article

User Sign In